• Subscribe
  • Webinars
  • White Papers
  • Buyer's Guide
  • PhotonicsNXT
  • Get Published!
    • Recent Quotes
    My Watchlist
    Indicators
    BioOptics Stock Watch
    Markets
    Stocks
    ETFs
    Tools
    Markets:
    Overview
    News
    Currencies
    International
    Treasuries

    Aardvark Therapeutics, Inc. - Common Stock (NQ:AARD)

    5.650 +0.420 (+8.03%)
    Streaming Delayed Price Updated: 4:00 PM EDT, Apr 20, 2026 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Price and Volume

    Detailed Quote
    Volume 242,469
    Open 5.160
    Bid (Size) 5.540 (1,000)
    Ask (Size) 5.940 (500)
    Prev. Close 5.230
    Today's Range 5.103 - 5.770
    52wk Range 3.350 - 17.94
    Shares Outstanding N/A
    Dividend Yield N/A
    Chart for (: )
    Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

    Top News

    More News
    News headline image
    INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Aardvark Therapeutics, Inc. - AARD
    From Pomerantz LLP
    Via GlobeNewswire
    News headline image
    Aardvark Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Updates
    From Aardvark Therapeutics, Inc.
    Via GlobeNewswire

    Performance

    YTD
    -57.2%
    -57.2%
    1 Month
    +38.8%
    +38.8%
    3 Month
    -63.6%
    -63.6%
    6 Month
    -54.0%
    -54.0%
    1 Year
    -20.6%
    -20.6%

    More News

    Read More
    News headline image
    INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Aardvark Therapeutics, Inc. - AARD
    From Pomerantz LLP
    Via GlobeNewswire
    News headline image
    INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Aardvark Therapeutics, Inc. - AARD
    From Pomerantz LLP
    Via GlobeNewswire
    News headline image
    AARD Investors Have Opportunity to Join Aardvark Therapeutics, Inc. Fraud Investigation with the Schall Law Firm
    From Schall Law
    Via GlobeNewswire
    News headline image
    INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Aardvark Therapeutics, Inc. - AARD
    From Pomerantz LLP
    Via GlobeNewswire
    Monday's session: top gainers and losers ↗
    Via Chartmill
    Let's uncover which stocks are experiencing notable gaps during today's session. ↗
    Via Chartmill
    News headline image
    AARD Stock Slumps 54% Pre-Market – Here’s Why Analysts Are Not ‘Comfortable’ With The Suspension Of A Key Phase 3 Trial ↗
    Via Stocktwits
    Get insights into the top gainers and losers of Monday's pre-market session. ↗
    Via Chartmill
    News headline image
    AARD Investors Have Opportunity to Join Aardvark Therapeutics, Inc. Fraud Investigation With the Schall Law Firm
    From The Schall Law Firm
    Via Business Wire
    News headline image
    Aardvark Therapeutics Becomes Next Pharma Player To Quit Prader-Willi Syndrome Drug Development Efforts ↗
    Via Stocktwits
    Top movers in Friday's after hours session ↗
    Via Chartmill
    News headline image
    Aardvark Therapeutics Announces Voluntary Pause of Phase 3 HERO Trial in Prader-Willi Syndrome
    From Aardvark Therapeutics, Inc.
    Via GlobeNewswire
    News headline image
    Aardvark Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
    From Aardvark Therapeutics, Inc.
    Via GlobeNewswire
    News headline image
    Aardvark Therapeutics Announces Leadership Appointments
    From Aardvark Therapeutics, Inc.
    Via GlobeNewswire
    News headline image
    Aardvark Therapeutics Announces Establishment of New U.S. Subsidiary to Support Development of Its Dermatology Pipeline; Bryan Jones Named Chief Executive Officer
    From Aardvark Therapeutics, Inc.
    Via GlobeNewswire
    News headline image
    Aardvark Therapeutics Announces FDA Submission and IRB Approval of Amended Trial Protocol for Lead Candidate ARD-101, Expanding Eligibility in Phase 3 Study of Prader-Willi Syndrome
    From Aardvark Therapeutics, Inc.
    Via GlobeNewswire
    News headline image
    Aardvark Therapeutics Announces First Patient Dosed in Australia in HERO Phase 3 Trial for Prader-Willi Syndrome
    From Aardvark Therapeutics, Inc.
    Via GlobeNewswire
    News headline image
    Let's take a look at the stocks that are in motion in today's session. ↗
    Via Chartmill
    News headline image
    These stocks are moving in today's session ↗
    Via Chartmill
    News headline image
    Which stocks are gapping on Wednesday? ↗
    Via Chartmill
    News headline image
    Which stocks are moving after the closing bell on Tuesday? ↗
    Via Chartmill
    News headline image
    Aardvark Therapeutics to Present at Upcoming Investor Conferences in December
    From Aardvark Therapeutics, Inc.
    Via GlobeNewswire
    News headline image
    Aardvark Therapeutics Reports Third Quarter 2025 Financial Results and Provides Pipeline and Business Updates
    From Aardvark Therapeutics, Inc.
    Via GlobeNewswire

    Frequently Asked Questions

    Is Aardvark Therapeutics, Inc. - Common Stock publicly traded?
    Yes, Aardvark Therapeutics, Inc. - Common Stock is publicly traded.
    What exchange does Aardvark Therapeutics, Inc. - Common Stock trade on?
    Aardvark Therapeutics, Inc. - Common Stock trades on the Nasdaq Stock Market
    What is the ticker symbol for Aardvark Therapeutics, Inc. - Common Stock?
    The ticker symbol for Aardvark Therapeutics, Inc. - Common Stock is AARD on the Nasdaq Stock Market
    What is the current price of Aardvark Therapeutics, Inc. - Common Stock?
    The current price of Aardvark Therapeutics, Inc. - Common Stock is 5.650
    When was Aardvark Therapeutics, Inc. - Common Stock last traded?
    The last trade of Aardvark Therapeutics, Inc. - Common Stock was at 04/20/26 04:00 PM ET
    Stock Quote API & Stock News API supplied by www.cloudquote.io
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the Privacy Policy and Terms Of Service.
    © 2025 FinancialContent. All rights reserved.